iSpecimen (NASDAQ:ISPC – Get Rating) and Protalex (OTCMKTS:PRTX – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Valuation and Earnings
This table compares iSpecimen and Protalex’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|iSpecimen||$11.14 million||1.70||-$8.96 million||N/A||N/A|
Protalex has lower revenue, but higher earnings than iSpecimen.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
iSpecimen presently has a consensus target price of $20.00, suggesting a potential upside of 838.97%. Given iSpecimen’s higher possible upside, research analysts clearly believe iSpecimen is more favorable than Protalex.
Insider & Institutional Ownership
4.2% of iSpecimen shares are held by institutional investors. 32.3% of iSpecimen shares are held by insiders. Comparatively, 80.0% of Protalex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares iSpecimen and Protalex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.